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Abstract: Metastatic bone cancer causes severe pain, but current treatments often provide 
insufficient pain relief. One of the reasons is that mechanisms underlying bone cancer pain are 
not solved completely. Our previous studies have shown that brain-derived neurotrophic fac-
tor (BDNF), known as a member of the neurotrophic family, is an important molecule in the 
pathological pain state in some pain models. We hypothesized that expression changes of BDNF 
may be one of the factors related to bone cancer pain; in this study, we investigated changes 
of BDNF expression in dorsal root ganglia in a rat bone cancer pain model. As we expected, 
BDNF mRNA (messenger ribonucleic acid) and protein were significantly increased in L3 dorsal 
root ganglia after intra-tibial inoculation of MRMT-1 rat breast cancer cells. Among the eleven 
splice-variants of BDNF mRNA, exon 1–9 variant increased predominantly. Interestingly, the 
up-regulation of BDNF is localized in small neurons (mostly nociceptive neurons) but not in 
medium or large neurons (non-nociceptive neurons). Further, expression of nerve growth factor 
(NGF), which is known as a specific promoter of BDNF exon 1–9 variant, was significantly 
increased in tibial bone marrow. Our findings suggest that BDNF is a key molecule in bone 
cancer pain, and NGF-BDNF cascade possibly develops bone cancer pain.
Keywords: BDNF, bone cancer pain, chronic pain, nerve growth factor
Introduction
Pain is one of the most feared and burdensome symptoms experienced by cancer 
patients. In a recent systematic review, 64% of advanced cancer patients were 
 suffering from severe cancer-related pain.1 In particular, cancer patients who develop 
bone metastasis experience significant pain, and drugs such as opioids and non-
steroidal anti-inflammatory drugs often provide an insufficient analgesic effect for 
such severe pain.
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophic 
family and plays important roles in survival, differentiation, and synaptic plasticity 
of neurons.2 BDNF is also implicated in the development of pathological pain. In the 
spinal dorsal horn, BDNF modulates pain transduction by several mechanisms, such 
as downregulation of potassium chloride co-transporter (KCC2) in a partial nerve 
ligation model3 and activation of N-methyl-D-aspartate receptor in an L5 spinal 
nerve ligation model.4 Between dorsal root ganglion (DRG) neurons, BDNF acts as 
an autocrine and/or paracrine signal in an inflammatory pain model and enhances 
release of neurotransmitter such as calcitonin-gene related protein and substance P.5 
BDNF expression is induced by nerve growth factor (NGF) in DRG neurons6 and 
by adenosine-5′-triphosphate in spinal microglia.3 While the mechanism of BDNF 
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induction is not fully understood in the bone cancer pain 
model, a recent study demonstrated that BDNF messenger 
ribonucleic acid (mRNA) expression increased in DRG, 
and small interfering RNA (siRNA)-mediated BDNF 
knockdown reduced the behavioral hypersensitivity in the 
rat bone cancer pain model induced by prostate cancer cell 
inoculation.7
The rat BDNF gene contains eight non-coding exons 
(exons 1 through 8) and one coding exon (exon 9).8 These 
non-coding exons can be spliced to the coding exon to form 
the following splice variants: exons 1–9, 2a–9, 2b–9, 2c–9, 
3–9, 4–9, 5–9, 6–9, 7–9, 8–9, and 9a–9. Expressions of these 
splice variants are regulated in an age- and organ-dependent 
manner.8 This finding would indicate that multiple promoters 
are regulating transcription of the splice variants in response 
to diverse environmental conditions. Our previous studies 
have clearly demonstrated that BDNF mRNA expression 
in DRG was up-regulated in inflammatory and neuropathic 
pain models, and the exon 1–9 variant showed the greatest 
responses in both models.9 We also reported that BDNF 
exon 1–9 was induced by NGF stimulation in cultured DRG 
neurons.10 These observations indicated that a specific variant 
of BDNF mRNA, exon 1–9, can be a strong indicator of 
various pain. We hypothesized that alternative expression of 
BDNF and NGF-BDNF cascade is also related to bone cancer 
pain. In this study, to address this issue, we investigated the 
expression profile of BDNF splice variants in DRGs in rat 
bone cancer pain model and the relation between NGF and 
BDNF expression.
Materials and methods
cell culture
MRMT-1 rat breast cancer cells were provided by the 
Cell Resource Center for Biomedical Research, Tohoku 
 University (Miyagi, Japan). Cells were cultured in RPMI 
1640 supplemented with 300 mg/mL L-glutamine, 
10% fetal bovine serum, 200 U/mL penicillin, and 
200 µg/mL  streptomycin, and incubated at 37°C in a humidi-
fied  atmosphere of 5% CO
2
.
animals
All animal procedures were carried out in accordance with the 
Ethical Guidelines for the Investigation of Experimental Pain 
in Conscious Animals issued by the International Association 
for the Study of Pain.11 The Board of Animal Care and Use 
Committee of Okayama University Medical School approved 
this study on 31 March 2010 (OKU-2010103, Chairman Prof 
M Nishibori).
Male Wistar rats (170–190 g at surgery, total 54 rats; 
CLEA Japan, Tokyo, Japan) were housed under controlled 
conditions (12 hours alternating light–dark cycle, food and 
water ad libitum).
surgical procedure
Injection of MRMT-1 cells was performed as described 
 previously.12 Briefly, all surgical procedures were performed 
under 1%–2% isoflurane inhalation anesthesia. After the 
induction of anesthesia, the left leg was shaved, and the skin 
was disinfected with 70% v/v ethanol. A 1 cm rostro-caudal 
incision was made in the skin over the top half of the surface 
of the proximal end of the tibia. A 24-gauge needle was 
inserted 5 mm below the knee joint into the intramedullary 
cavity of the tibia. A cell suspension containing 3×103 
MRMT-1 cells in 10 µL of Hank’s buffered sterile saline 
(HBSS) buffer (Sigma-Aldrich, St Louis, MO, USA) was 
injected into the medullary space of the left tibia with a 10 µL 
Hamilton syringe (MRMT-1 group). Control animals were 
injected with the same volume of HBSS buffer only (Sham 
group). The injection site was sealed with bone wax, and then 
the wound was closed, and gentamicin sulfate ointment was 
applied. After the surgery, the rats were placed in a thermo-
regulated recovery box until they had regained consciousness, 
and they were then returned to the home cage.
Radiological analysis
Roentgenography of the ipsilateral tibia was performed 
 preoperatively and on postoperative days 7 and 14. 
 Radiographs were taken by a Latheta LCT-200 X-ray 
imaging system (Hitachi Aloka Medical, Mitaka, Tokyo, 
Japan) under sodium pentobarbital anesthesia (50 mg/kg, 
intraperitoneally). After the examination, the rats were 
placed in a thermo-regulated recovery box until they had 
regained consciousness, and they were then returned to the 
home cage.
Behavioral assessment
Pain behavior was assessed by the von Frey test and measure-
ment of hind limb weight-bearing before and 1–14 days after 
the surgery. Mechanical allodynia was measured as the hind 
paw withdrawal threshold (PWT) with von Frey filaments 
(Touch-Test® Sensory Evaluator; North Coast Medical, 
Morgan Hill, CA, USA). The rats were placed individually 
in a plastic cage (13 × 10 × 15 cm3) with an elevated wire 
mesh bottom, allowing full access to the plantar surfaces of 
both hind paws. The mechanical stimuli were applied to the 
medial plantar aspect of each hind paw with one of a series 
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Figure 1 BDnF gene structure and primer set.
Abbreviations: BDnF, brain-derived neurotrophic factor; cDs, coding sequences.
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of nine von Frey filaments (0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 
8.0, and 15.0 g). Each trial was started with a von Frey force 
of 2 g for 1–2 seconds. Stimuli were presented at intervals of 
at least 10 seconds, allowing for apparent resolution of any 
behavioral responses to previous stimuli. On the basis of the 
response pattern and the force of the final filament, the 50% 
PWT was determined by the up–down method of Dixon13 
and calculated using the formula described by Chaplan et al.14 
If the strongest filament did not elicit a response, the PWT 
was recorded as 15.0 g.
Hind limb weight-bearing was measured by an 
Incapacitance Tester (Linton Instrumentation, Norfolk, 
UK) as described by Fernihough et al.15 The rat was placed 
in a chamber so that each hind paw was resting on a separate 
force transducer pad. Each transducer pad recorded a body-
weight on each paw four times in 1 second, and the testing 
duration was set to 3 seconds. Five readings were averaged 
for each hind paw, and the results were presented as the 
weight-bearing ratio (ipsilateral/contralateral).
Quantitative real-time reverse  
transcription (RT)-polymerase  
chain reaction (PcR)
After carrying out behavioral assessment, rats were sacri-
ficed by decapitation under deep ether anesthesia 14 days 
after the surgery. Ipsilateral L3, L4, and L5 DRG were 
dissected rapidly and dipped immediately in RNAlater 
(Qiagen Inc., Valencia, CA, USA). Tibial bone marrow was 
collected by flushing 100 µL of RNAlater in the tibial cavity. 
Total RNA was isolated and purified from individual DRG, 
and the bone marrow with RNeasy Lipid Tissue Mini Kit 
(Qiagen Inc.). In this process, DNAse I was used for removal 
of genomic DNA according to manufacturer’s instruction. 
Removal of genomic DNA was confirmed by PCR of total 
RNA with BDNF exon 9 primers (no RT control). Then, 1 µg 
of total RNA was reverse-transcribed with the Ready-To-Go 
T-primed First-Strand Kit (GE Healthcare Life Sciences, 
Buckinghamshire, UK). cDNA solutions were diluted ten-
fold with DNase-free water. Complementary DNA (cDNA) 
was amplified in a 20 µL real-time PCR reaction mixture 
containing 10 µL SYBR Premix Ex Taq (Takara-Bio, Otsu, 
Japan), 4.2 µL DNase-free water, 0.2 µM each of forward 
and reverse primers, and 5 µL diluted cDNA solution. The 
forward primer for each BDNF splice variant was designed 
from each non-coding exon, and the reverse primer was 
designed from the coding region in exon 9 (Figure 1). To 
quantify expression of total BDNF, forward and reverse 
primers were both designed from exon 9. The sequences 
of primer sets are shown in Table 1.  Quantitative real-
time RT-PCR was performed with a LightCycler® (Roche 
Diagnostics Corporation, Indianapolis, IN, USA) with the 
following amplification conditions: 95°C for 10 seconds 
followed by 45 cycles of 5 seconds at 95°C and 20 seconds 
at 60°C. To quantify absolute cDNA copy numbers, stan-
dard curves were created by the following method. Each 
PCR product with the quantitative primers was cloned into 
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Table 1 Oligonucleotide sequences of primers for real-time RT-PcR
Target cDNA GenBank  
acc no
Forward primers 
(5′ to 3′)
Reverse primers 
(5′ to 3′)
Amplicon 
size (bp)
BDnF 1–9 eF125675 tgttggggagacgagatttt cgtggacgtttgcttctttc 159
BDnF 2a–9 eF125676 tacttcatccagttccaccag caagttgccttgtccgt 129
BDnF 2b–9 eF125677 aagctccggttccaccag tgcttctttcatgggcg 102
BDnF 2c–9 eF125678 gtggtgtaagccgcaaaga cgtggacgtttgcttctttc 124
BDnF 3–9 eF125686 ctgagactgcgctccactc gtggacgtttgcttctttca 152
BDnF 4–9 eF125679 gagcagctgccttgatgttt gtggacgtttgcttctttca 148
BDnF 5–9 eF125687 accccgcacactctgtgta acagctgggtaggccaagtt 204
BDnF 6–9 eF125680 gatccgagagctttgtgtgg gtggacgtttgcttctttca 130
BDnF 8–9 eF125689 cagtggagctgaacaaacga gccttcatgcaaccgaagta 117
BDnF 9a–9 eF125690 gtctctgcttccttcccaca cgtggacgtttgcttctttc 124
Total BDnF nM_012513 gcggcagataaaaagactgc gcagccttccttcgtgtaac 141
Trka nM_021589 ttctcaagtgggagctaggg ctctgcctcacgatggaagt 155
RPl27 nM_022514 gaattgaccgctatcccaga tcgctcctcaaacttgacct 200
Notes: The forward primer for each BDnF splice variant is designed from each non-coding exon. The forward primer for total BDnF is designed from exon 9. all reverse 
primers except Trka and RPl27 are designed from exon 9.
Abbreviations: BDnF, brain-derived neurotrophic factor; RPl27, 60s ribosomal protein l27; RT-PcR, reverse transcription (RT)-polymerase chain reaction; 
Trka, tropomyosin receptor kinase a; bp, base pairs.
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pCRII-TOPO (Life Technologies, Carlsbad, CA, USA), 
and the insert was amplified with M13 forward and reverse 
primers. The amplified inserts were isolated by agarose gel 
electrophoresis, extracted from the gel. The concentrations 
of the oligonucleotides in the gel extracts were measured 
by spectrophotometry. Absolute copy numbers of the oli-
gonucleotides were calculated from the concentrations and 
diluted serially to generate standard curves. Expression of 
each mRNA was normalized to expression of 60S ribosomal 
protein L27 (RPL27).16 The data were shown as percentage 
to mean values of the sham group. PCR specificity was 
confirmed by sequencing, agarose gel electrophoresis, and 
melting curve analysis.
immunohistochemistry
Rats were anesthetized deeply with ether and perfused tran-
scardially with 50 mL of saline, followed by 500 mL of 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The 
L3, L4, and L5 DRG were dissected and post-fixed in the 
same fixative for 30 minutes, incubated in phosphate-buffered 
20% sucrose solution overnight. These tissues were embedded 
in OCT compound (Tissue-tek®; Sakura Finetek, Tokyo, 
Japan) and 8 µm thick frozen sections were cut. For visual-
ization of BDNF in the DRG, the avidin-biotin-horseradish 
peroxidase complex method was used. These sections were 
incubated overnight with rabbit anti-BDNF antibody (1:4000, 
#sc-546; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
 followed by incubation with biotinylated goat anti-rabbit IgG 
 (immunoglobulin G) (1:200) and avidin-biotin-horseradish 
peroxidase complex (Vector Laboratories, Burlingame, 
CA, USA).  Immunoreaction products were visualized with 
diaminobenzidine and nickel ammonium sulfate. DRG neu-
rons were categorized as small (,20 µm diameter), medium 
(20–40 µm diameter), and large (.40 µm diameter), and 
the proportion of BDNF-immunoreactive (IR) neurons was 
analyzed in each group. The cell counting was performed by a 
blinded observer. Three representative sections that contained 
over 70 neurons, total at least 210 each neuron, with distinct 
nuclei were randomly selected in each of the DRG.
statistical analysis
Data are presented as means ± standard deviation. The data 
of hind limb weight-bearing and tactile withdrawal thresholds 
with von Frey filaments were analyzed by two-way ANOVA 
(analysis of variance) followed by Scheffe’s F-test. Data on 
real-time RT-PCR analysis and the proportion of BDNF-IR 
neurons were analyzed by Student’s t-test. P,0.05 was 
considered significant.
Results
Osteopenia and pain-related behavior  
after cancer cell inoculation
Osteopenia caused by growth of inoculated cells was 
observed in the MRMT-1 group postoperatively (Figure 2A). 
While osteopenia was gradually increased through day 7–14, 
cortical integrity was maintained at day 14. This phenomenon 
represents to clinical observation that bone metastatic cancer 
cells grow in tibia of a breast cancer patient. It sometimes 
causes osteolysis. No radiological changes were found in 
the sham group.
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Figure 2 (A) Radiographs of left tibiae inoculated with MRMT-1 breast cancer cells or vehicle. The white arrow indicates the MRMT-1 injection site. (B) Time course of 
the ipsilateral PWT to mechanical stimuli after intra-tibial inoculations of hank’s buffered sterile saline (white box, n=6) and MRMT-1 cells (black box, n=6). These data are 
reported as means ± sD. **P,0.01 versus sham group. (C) Time course of the contralateral PWT to mechanical stimuli after intra-tibial inoculations of hank’s buffered sterile 
saline (white triangle, n=6) and MRMT-1 cells (cross mark, n=6). These data are reported as means ± sD. **P,0.01 versus sham group. (D) Time course of the hind limb 
weight-bearing ratio (ipsilateral/contralateral) in rats that received intra-tibial inoculations of hank’s buffered sterile saline (white box) (n=6) and MRMT-1 cells (black box) 
(n=6). These data are reported as means ± sD. **P,0.01 versus sham group.
Abbreviations: PWT, paw withdrawal threshold; sD, standard deviation.
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During the observation period, rats with MRMT-1 walked 
with mild claudication. This observation showed that cancer 
inoculation did not influence motility nor cause bone fractures 
at least in the observation period as radiographs also showed. 
Pain-related behavior was assessed by the von Frey tests (Fig-
ure 2B and C) and the hind limb weight-bearing tests (Figure 
2D). Prior to intramedullary injection of MRMT-1 or vehicle, 
there was no difference in ipsilateral 50% PWT between 
the MRMT-1 group and the sham group. After the injection 
of MRMT-1, the ipsilateral 50% PWT was decreased sig-
nificantly on day 9 (MRMT-1 group 6.2±2.0 g versus sham 
group 14.8±0.4 g, P,0.01) (Figure 2B). The decreased 50% 
PWT was continuously observed until day 14 at the end of 
the observation period. The contralateral hind limb showed 
no pain-related behavior in both the MRMT-1 group and 
sham group during the observation period  (Figure 2C). Rats 
injected with MRMT-1 cells showed significant reduction 
in weight-bearing on the left hind limb beginning on day 12 
(MRMT-1 group 0.69±0.19 versus sham group 1.01±0.03, 
P,0.05, Figure 2D). These pain-related behaviors progressed 
along with the growth of the bone cancer seen in the 
radiographs (Figure 2A).
BDnF mRna and protein was increased 
in l3 DRg after cancer cell inoculation
Increased BDNF levels in DRG were reported in some pain 
models and were thought to be involved in pain development. 
We investigated BDNF expression and localization in DRG 
neurons. Total BDNF mRNA expression in L3, L4, and L5 
DRG are shown in Figure 3A. In the MRMT-1 group, the 
expression of total BDNF mRNA in L3 DRG increased sig-
nificantly to 119% compared with the sham group (P,0.05). 
However, no significant differences in the expressions of total 
BDNF mRNA in the L4 and L5 DRG were seen between 
the two groups.
To further investigate the expression profiles of BDNF 
mRNA, expressions of BDNF splice variants were studied. 
Among all splice variants, exon 1–9 showed the greatest 
increase, to 207% compared with the sham group (P,0.01). 
Expressions of exons 2a–9, 2b–9, 2c–9, 4-9, and 6–9 also 
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Figure 3 (A) Relative expression of BDnF mRna in the ipsilateral l3, l4, and l5 DRg 14 days after MRMT-1 inoculation. These data are shown as percentage to mean 
values of the sham group. Black bars and gray bars indicate the MRMT-1 groups (n=6) and sham groups (n=6), respectively. These data are reported as mean ± sD. *P,0.05, 
versus sham group. (B) Relative expression BDnF splice variants in the ipsilateral l3 DRg 14 days after MRMT-1 inoculation. These data are shown as percentage to mean 
values of the sham group. Black bars and gray bars indicate MRMT-1 groups (n=6) and sham groups (n=6), respectively. These data are reported as mean ± sD. *P,0.05, 
**P,0.01 versus sham group. (C) Photomicrographs showing the ipsilateral l3 DRg in the MRMT-1 group and sham group 14 days after surgery. arrows indicate BDnF-
positive small sized neurons (,20 µm), and arrowheads indicate BDnF-positive medium sized neurons (20–40 µm).
Abbreviations: BDnF, brain-derived neurotrophic factor; DRg, dorsal root ganglion; mRna, messenger ribonucleic acid; sD, standard deviation.
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increased significantly to 161%, 159%, 133%, 142%, 
and 137% compared with the sham group, respectively 
(exon 2c–9, P,0.05; other exons, P,0.01) (Figure 3B). 
 Expression of exon 3–9 and 9a–9 did not change. Since the 
absolute copy numbers of exon 5–9 and 8–9 were each below 
10 copies/µL, which was under the lower limit for quantifica-
tion, data for these exons were excluded from analysis. We 
could not amplify exon 7–9 in rat neuronal cDNA despite 
our best efforts. No significant differences in the expressions 
of BDNF mRNA splice variants in the L4 and L5 DRG were 
found between the MRMT-1 group and the sham group, as 
well as in total BDNF mRNA (data not shown).
Figure 3C shows representative photomicrographs of 
the L3 DRG on day 14. The percentages of BDNF-positive 
neurons of the left L3, L4, and L5 DRG are shown in Table 2. 
While the percentage of BDNF-positive neurons in the sham 
group was similar to a previous report,17 our new finding 
was that BDNF in L3 DRG was significantly increased by 
MRMT-1 inoculation in only small-sized neurons (136% 
versus sham group, P,0.01) but not in medium- or large-
sized neurons (Table 2).
ngF is one of the key regulators  
of BDnF in bone cancer pain model
Since BDNF expression in DRG is reported to be induced 
by systemic administration of NGF,6 and further BDNF 
exon 1–9 variant contributes a considerable part of the 
NGF- induced expression of BDNF mRNA,10 we investigated 
NGF expression in the tibial cavity. Quantitative real-time 
RT-PCR revealed a robust increase of NGF mRNA in the 
MRMT-1 group (3.8-fold versus sham group, P,0.01) 
(Figure 4).
Since NGF mRNA was increased in the tibial 
cavity after MRMT-1 inoculation, we investigated 
Journal of Pain Research 2014:7
Table 2 expression and localization of BDnF in l3, l4, and 
l5 DRg
DRG  
neurona
MRMT-1 
group (%)b
Sham  
group (%)b
MRMT-1/ 
sham (-fold)
P-valuec
l3
 Total 15.59±1.42 11.62±0.61 1.34 0.0022**
 small 35.89±2.11 26.32±1.66 1.36 0.00038**
 Medium 13.18±2.45 11.26±1.51 1.17 0.23
 large 3.11±0.99 1.55±1.24 2.00 0.23
l4
 Total 13.73±3.79 11.80±2.19 1.16 0.41
 small 30.01±4.77 26.85±1.77 1.11 0.26
 Medium 13.52±3.72 11.51±3.46 1.17 0.45
 large 3.56±2.73 3.33±1.75 1.06 0.89
l5
 Total 12.73±3.01 9.53±1.26 1.34 0.098
 small 26.65±2.14 25.29±2.95 1.05 0.48
 Medium 11.59±3.97 8.69±1.27 1.33 0.21
 large 4.11±2.65 2.00±0.84a 2.05 0.18
Notes: aDRg neurons were categorized as small (,20 µm), medium (20–40 µm), 
and large (.40 µm); bthe data are described as a percentage of BDnF-iR neurons 
of each group (n=4). The data are reported as mean ± sD; cMRMT-1 versus sham 
group; **P,0.01 versus sham group.
Abbreviations: BDnF, brain-derived neurotrophic factor; DRg, dorsal root 
ganglion; iR, immunoreactive; sD, standard deviation.
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expression of NGF receptor, tropomyosin receptor kinase 
A (TrkA) mRNA in L3 DRG. In the MRMT-1 group, 
 expression of TrkA mRNA was increased significantly 
to 193%  compared with the sham group (P,0.01, 
Figure 5).
Discussion
In this study, we found that inoculation of MRMT-1 cancer 
cells induced pain-related behavior, and the proportion of 
BDNF-IR-positive neurons were increased significantly 
in small neurons in the L3 DRG. Up-regulation of BDNF 
mRNA in the L3 DRG after MRMT-1 inoculation was 
observed. Further for detail, among the splice variants, the 
exon 1–9 variant showed the greatest increase in this model. 
This report functions as the first report showing the profile 
of BDNF splice variants in rat bone cancer pain. Expression 
of NGF, which is known to induce BDNF in DRG neurons, 
was increased in the intra-tibial cavity with MRMT-1 cells, 
and its high affinity receptor TrkA was increased in L3 DRG. 
Our results imply that NGF up-regulation in the tibia play a 
role in BDNF induction.
The role of BDNF in the development of pathological 
pain has been well described. BDNF in the spinal dorsal horn 
modulates synaptic transmission by several mechanisms,18 
including downregulation of KCC2 transporter and con-
version of inhibitory GABAergic neurons to excitatory.3 
Although Coull et al3 regarded spinal microglia as a source of 
BDNF,3 anterograde transport of BDNF from DRG sensory 
neurons contributes to the increase of BDNF in the spinal 
dorsal horn.19 BDNF also acts as autocrine and/or paracrine 
signal between DRG neurons. Up-regulation of BDNF and 
TrkB receptor were reported in an inflammatory pain model, 
and BDNF stimulation increased release of neurotransmitter 
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such as calcitonin-gene related protein and substance P in 
cultured DRG neurons.5 Extensive evidence indicates BDNF 
roles in development of pathological pain in inflammatory20 
and neuropathic21 pain models. It has also been reported that 
BDNF mRNA expression was increased in L4–L6 DRG in 
a rat bone cancer pain model with Walker 256 mammary 
grand carcinoma cell inoculation.7 In the present study, 
we confirmed that BDNF-positive neurons were increased 
in L3 DRG after MRMT-1 inoculation. Consistently, the 
report studied by intra-tibial injection of retrograde tracer 
suggested that tibial bone marrow was innervated mainly by 
L3 DRG neuron.22 Taken together with the present study, our 
novel finding that BDNF-positive neurons were increased in 
L3 DRG after MRMT-1 inoculation is convincing.
Blockade of BDNF reduces the pain behavior in bone 
cancer pain,7 neuropathic pain,23 and inflammatory pain24 
models. However, suppression of BDNF was documented 
to result in serious adverse effects, such as early postnatal 
death in homozygous knockout mouse,25 decrease or loss 
of the sensory nervous system in heterozygous knockout 
mouse,26 and learning disturbance and memory disorder 
after the injection of anti-BDNF antibody into the cerebral 
ventricle.27 To avoid these effects resulting from systemic 
blockade of BDNF, local BDNF suppression (eg, intrath-
ecal injection of siRNA,28 DRG-specific vector transfer 
mediated by intrathecal injection of AAV829) can be a possible 
therapeutic tool for pain conditions. We previously reported 
predominant up-regulation of BDNF exon 1–9 mRNA among 
the splice variants in L4 and L5 DRG in inflammatory and 
neuropathic pain models.9 We also reported that DNA decoy 
targeting BDNF exon 1 promoter activity showed the anti-
nociceptive effect in a rat neuropathic pain model.30 Since 
the exon 1–9 variant showed the highest increase in the 
present study, as well as in other pain models, suppression 
of BDNF exon 1 transcription might be a therapeutic target 
for bone cancer pain.
We observed up-regulation of BDNF protein in small 
neurons in L3 DRG. The majority of small neurons express 
TrkA, high affinity NGF receptor, and almost all TrkA-
positive cells express calcitonin gene-related peptide 
immunoreactivity.31 These facts indicate the majority of small 
neurons are nociceptive and responsive to NGF. On the other 
hand, most large neurons, which convey proprioception via 
A-beta fiber, do not express TrkA.31 Our immunohistochemi-
cal results suggest the role of BDNF in cancer-induced bone 
pain and possible involvement of NGF-TrkA signaling in 
BDNF up-regulation. Medium to large DRG neurons are 
reported to change their phenotype and turn to produce 
BDNF in pain models accompanying axotomy.32 We did not 
observe an increase of BDNF in medium and large neurons 
in this model.
In the present study, NGF mRNA expression was 
increased in the intra-tibial cavity in MRMT-1 inoculated 
rats. In the intra-tibial cavity, MRMT-1 cells are thought to 
produce NGF. Several lines of evidence on NGF induction 
of BDNF have been reported. Cultured DRG neurons 
up-regulate BDNF mRNA in response to NGF stimula-
tion in a dose-dependent manner.10 We also observed TrkA 
mRNA expression was increased in the L3 DRG after 
intra-tibial inoculation of MRMT-1. NGF-TrkA complex 
is internalized and transported from peripheral terminals to 
sensory cell bodies in the DRG33 and activates transcription 
factors that control downstream gene expression.33 Systemic 
administration of NGF to rats induced BDNF mRNA in 
DRG neurons expressing TrkA receptors.6 Long-term NGF 
stimulation induced TrkA mRNA and enhanced intracellular 
signaling in PC12 cells.34 Sensory nerve fibers sprouting to 
bone cancer35 express TrkA receptor. These findings support 
the involvement of the NGF-TrkA-BDNF cascade in the 
present study. Importantly, NGF expression in breast cancer 
tissue is not limited to experimental conditions. It has been 
reported that biopsies of human breast cancer showed strong 
NGF immunoreactivity in most specimens.36,37
The limitation of our study is that we do not directly prove 
involvement of cancer-derived NGF in BDNF induction and 
pain-related behavior. To clarify the involvement of NGF and 
BDNF in bone cancer pain, further study is required.
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